These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 6170889)
1. Diabetes resistant to subcutaneous insulin: effect of aprotinin. N Engl J Med; 1981 Dec; 305(23):1413-4. PubMed ID: 6170889 [No Abstract] [Full Text] [Related]
2. Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin. Freidenberg GR; White N; Cataland S; O'Dorisio TM; Sotos JF; Santiago JV N Engl J Med; 1981 Aug; 305(7):363-8. PubMed ID: 7019707 [TBL] [Abstract][Full Text] [Related]
3. [Estimation of daily insulin requirement in diabetes using intravenous infusion of insulin]. Lawecki J; Krzymień J Pol Tyg Lek; 1979 Jan; 34(3):81-4. PubMed ID: 424341 [No Abstract] [Full Text] [Related]
4. [The treatment of diabetes mellitus using continuous subcutaneous infusion]. van Ballegooie E; Sluiter WJ; Reitsma WD; Doorenbos H Ned Tijdschr Geneeskd; 1980 Nov; 124(48):2038-42. PubMed ID: 7003403 [No Abstract] [Full Text] [Related]
5. [Causes and the principles of treatment in insulin-dependent diabetes mellitus (type I)]. Waldhäusl W Pol Tyg Lek; 1982 Dec; 37(51-52):1591-4. PubMed ID: 6763993 [No Abstract] [Full Text] [Related]
6. Aprotinin induced lipohypertrophy and glomerulonephritis in an insulin dependent diabetic. Dandona P; Mier A; Boag F; Chappell M; Beckett AG Diabetes Res; 1985 Jul; 2(4):213-6. PubMed ID: 2417774 [TBL] [Abstract][Full Text] [Related]
7. Resistance against subcutaneous insulin successfully managed with aprotinin. Müller WA; Taillens C; Léreret S; Berger M; Philippe J; Halban PA; Offord RE Lancet; 1980 Jun; 1(8180):1245-6. PubMed ID: 6155578 [No Abstract] [Full Text] [Related]
8. [Efficacy of aprotinin in insulin resistance caused by subcutaneous degradation of insulin]. Sudre Y; Marechaud R; Abadie JC; Rossi F; Gouet D Nouv Presse Med; 1982 Jan; 11(2):131-2. PubMed ID: 6173842 [No Abstract] [Full Text] [Related]
9. The perioperative management of diabetes. Nel CJ; de Waal JM; Steyn AF S Afr J Surg; 1980 Sep; 19(3):107-12. PubMed ID: 7003762 [No Abstract] [Full Text] [Related]
10. [Coincidence of hepatic angiosarcoma and insulin-resistance diabetes mellitus with high-dose intraperitoneal insulin therapy]. Kersten A; Schwarzkopf J; Petersen KG; Lohner M Verh Dtsch Ges Pathol; 1994; 78():285-7. PubMed ID: 7534000 [TBL] [Abstract][Full Text] [Related]
12. Medical Grand Rounds. Open and closed loop insulin delivery systems in diabetes: current status. Service FJ Henry Ford Hosp Med J; 1982; 30(3):163-7. PubMed ID: 6761321 [No Abstract] [Full Text] [Related]
13. Twenty-four hour blood glucose profiles during insulin and insulin plus aprotinin subcutaneous administration in type I diabetes. Lunetta M; Napoli E; Sudano L; Leonardi R; Mughini L Horm Metab Res; 1986 Mar; 18(3):182-4. PubMed ID: 2422103 [TBL] [Abstract][Full Text] [Related]
19. Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes. Darmon P; Curtillet C; Boullu S; Laugier A; Dutour A; Oliver C Diabetes Care; 1998 Sep; 21(9):1575. PubMed ID: 9727917 [No Abstract] [Full Text] [Related]
20. Use of continuous subcutaneous insulin infusion pumps--Georgia, Maine, and Nebraska. Centers for Disease Control (CDC) MMWR Morb Mortal Wkly Rep; 1982 Jan; 31(1-2):5-6, 15. PubMed ID: 6798419 [No Abstract] [Full Text] [Related] [Next] [New Search]